Ocuphire Pharma, Inc.
NASDAQ Capital MarketTotal Valuation
Ocuphire Pharma, Inc. carries a market capitalization of 31.74M, placing it among publicly traded companies globally.
| Market Cap | 31.74M |
| Enterprise Value | N/A |
Share Statistics
Ocuphire Pharma, Inc. currently has 25.98M shares outstanding.
| Shares Outstanding | 25.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.99, and the price-to-book ratio stands at -0.32.
| PE Ratio | N/A |
| PS Ratio | 3.99 |
| PB Ratio | -0.32 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | -2.46 |
| P/OCF Ratio | -2.46 |
Financial Position
Ocuphire Pharma, Inc. maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.63 |
| Quick Ratio | 6.56 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -57.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -2,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ocuphire Pharma, Inc.'s stock has declined approximately -58.36299% over the past 52 weeks. The 50-day moving average sits at 1.27, while the 200-day moving average is 1.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | -58.36299% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.74 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ocuphire Pharma, Inc. generated 8.38M in revenue and converted that into -27.19M in net income, yielding earnings per share of -1.07. EBITDA reached -29.47M, while operating income came in at -29.47M.
| Revenue | 8.38M |
| Gross Profit | N/A |
| Operating Income | -29.47M |
| Pretax Income | -27.19M |
| Net Income | -27.19M |
| EBITDA | -29.47M |
| EBIT | -29.47M |
| Earnings Per Share (EPS) | -1.07 |
Balance Sheet
Total book value stands at -103.86M, with working capital of 34.30M providing operational flexibility.
| Cash & Cash Equivalents | 36.64M |
| Total Debt | N/A |
| Net Debt | -36.63M |
| Equity (Book Value) | -103.86M |
| Book Value Per Share | -4.07 |
| Working Capital | 34.30M |
Cash Flow
Ocuphire Pharma, Inc. produced -13.59M in operating cash flow over the past twelve months.
| Operating Cash Flow | -13.59M |
| Capital Expenditures | N/A |
| Free Cash Flow | -13.59M |
| FCF Per Share | -0.53 |
Margins
Ocuphire Pharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -351.68 and net profit margin of -324.45 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -351.68 |
| Pretax Margin | -324.47 |
| Profit Margin | -324.45 |
| EBITDA Margin | -351.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.57 |
| FCF Yield | -40.69 |
Stock Splits
Ocuphire Pharma, Inc.'s most recent stock split took place on November 6, 2020 with a 4:1 split ratio.
| Last Split Date | 11/6/2020 |
| Split Ratio | 4:1 |
Scores
Ocuphire Pharma, Inc. posts an Altman Z-Score of -1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.49 |